Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

Avalo Therapeutics (AVTX) Receivables - Net (2016 - 2023)

Avalo Therapeutics (AVTX) has disclosed Receivables - Net for 8 consecutive years, with $38000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Receivables - Net fell 93.01% year-over-year to $38000.0, compared with a TTM value of $38000.0 through Jun 2023, down 93.01%, and an annual FY2021 reading of $1.1 million, down 51.31% over the prior year.
  • Receivables - Net was $38000.0 for Q2 2023 at Avalo Therapeutics, down from $544000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $5.0 million in Q3 2019 and bottomed at $38000.0 in Q2 2023.
  • Average Receivables - Net over 5 years is $2.1 million, with a median of $2.0 million recorded in 2020.
  • The sharpest move saw Receivables - Net soared 117.34% in 2020, then tumbled 93.01% in 2023.
  • Year by year, Receivables - Net stood at $1.0 million in 2019, then surged by 117.34% to $2.2 million in 2020, then crashed by 51.31% to $1.1 million in 2021, then plummeted by 48.68% to $544000.0 in 2022, then crashed by 93.01% to $38000.0 in 2023.
  • Business Quant data shows Receivables - Net for AVTX at $38000.0 in Q2 2023, $544000.0 in Q2 2022, and $938000.0 in Q1 2022.